Dallas-based Neos Therapeutics, Inc. recently renounced that Richard I. Eisenstadt has been named as the company’s new Chief Financial Officer (CFO).
The financial operations of the company, which is specialized in oral drug delivery, will become Eisenstadt’s responsibility effective immediately.
Neos Therapeutics’ President and Chief Executive Officer, Vipin Garg, said that he is “excited to welcome Rich to the Neos team. He brings an extensive track record of finance and business experience and a broad understanding of funding and managing growth companies. Rich will work closely with the organization and financial community to ensure funding of our existing pipeline, and expansion of the use of our proprietary controlled release technologies to create additional CR orally disintegrating tablets and CR liquids to bring to market.”
Richard I. Eisenstadt has worked in leading financial departments for over twenty-five year in the areas of healthcare, life sciences, and emerging technology industries, and was until now CFO of ArborGen Inc., a company that develops and commercializes technology for improving the productivity of the forestry industry.
Prior to his work at ArborGen Inc, as Vice President of Finance and Chief Financial Officer of Tranzyme Pharma, an investigational drug company. Mr. Eisenstadt was able to rise over $100 million in private and public equity and debt financing, including an initial public offering of the company’s stock in April 2011.
Previous work experience includes Director of Finance at Cogent Neuroscience and financial leadership positions at Nimbus CD International and Genicom Corporation.
Richard I. Eisenstadt has a MBA from James Madison University and a BA in Economics from the University of North Carolina at Chapel Hill. In 2011, the Triangle Business Journal awarded him with the reward CFO of the Year.
Neos Therapeutics Inc. is a pharmaceutical company that seeks to produce drugs approved by the FDA, which reduces the risks and costs of development and regulation. The company’s products are created with technologies that deliver controlled release small molecule active pharmaceutical ingredients in either liquid or orally disintegrating tablet (ODT) dosage forms.